Arvinas Inc
Research Arvinas Inc (ARVN) on Bullrun: market cap USD 498.89M, P/E 47.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARVN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 498.89M
- P/E47.6
- Financial periodQ2 2026
- RevenueUSD 249.70M
- Net incomeUSD 169.40M
- Free cash flow-USD 48.50M
Valuation Snapshot
latest market cap is USD 498.89M; P/E is 47.6.
Peer valuation comparison
Latest P/E is 47.63x versus a Healthcare sector median of 24.61x (93.6% above).
Latest P/E is 47.63x versus a United States median of 23.85x (99.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 262.60M | -USD 81.00M | -USD 275.70M | n/a | -1.14 | USD 142.90M | USD 600.00K | USD 433.90M |
| FY2024 | USD 263.40M | -USD 199.00M | -USD 261.10M | n/a | -2.77 | USD 100.50M | USD 800.00K | USD 561.70M |
| FY2023 | USD 78.50M | -USD 367.00M | -USD 350.70M | n/a | -6.62 | USD 311.70M | USD 1.00M | USD 660.00M |
| FY2022 | USD 131.40M | -USD 283.00M | -USD 280.30M | n/a | -5.31 | USD 81.30M | USD 1.00M | USD 564.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 498.89M | 47.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 753.11M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.32B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.80B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.82B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 4.34B | n/a | n/a | n/a |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Arvinas Inc's market cap?
Arvinas Inc's market capitalization is USD 498.89M.
What is Arvinas Inc's P/E ratio?
Arvinas Inc's price-to-earnings (P/E) ratio is 47.6.
What does Arvinas Inc do?
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.